食管胃结合部腺癌外科治疗中国专家共识（2018年版）

Chinese expert consensus on the surgical treatment for adenocarcinoma of esophagogastric junction （2018 edition）

食管胃结合部腺癌（AEG）的发病率呈现明显上升趋势。由于该疾病解剖部位的特殊性，其定义、分型、分期、手术路径、切除范围、淋巴结清扫规范、新辅助治疗等尚存在诸多争议。本共识旨在增强我国胸外科和胃肠外科医生对该疾病认识的同质性．以期规范AEG的外科治疗方式。本共识的达成基于当前最佳临床研究证据，参考最新国际指南与共识，结合中国外科专家组意见。针对上述争议领域．本共识共提出27项AEG外科治疗相关的推荐陈述．以及9项尚属于外科治疗相关待探索的问题。在本共识中未解决的相关问题，尚需积极开展高质量的临床研究逐步探索和解决。

Incidence of adenocarcinoma of esophago- gastric junction （AEG） in China presents an obviously increasing trend. Due to the particular anatomic site, its definition, classification, staging, surgical approach, resection pattern, extent of lymphadenectomy, and neoadjuvant therapy, etc. remain controversial. The goal of this expert consensus is to improve the homogeneity in understanding and practice among Chinese thoracic and gastrointestinal surgeons, and to further standardize surgical treatment of AEG. This consensus was generated based on the best available clinical evidence, the latest global guidelines or consensuses, and the agreement from the Chinese expert panel. The panel composed of 19 thoracic surgeons and 20 gastrointestinal surgeons nationwide. Delphi technique was used to generate agreement rates and revision details. In the fields of aforementioned controversies, the present consensus produced 27 statements on surgical treatment-related recommendations for AEG, as well as 9 issues as investigational surgical concerns. The present consensus consists of 7 parts： （1） definition and classification of AEG; （2） surgical approach; （3） minimally invasive surgery; （4） pattern and extent of resection; （5） combined organ resection; （6） lymph node group and lymphadenectomy standard; and （7） neoadjuvant therapy. Pending issues in this consensus need further high- quality clinical research.